
We are entering an era where "cure," specifically a functional cure, is no longer a forbidden word in the myeloma community.

We are entering an era where "cure," specifically a functional cure, is no longer a forbidden word in the myeloma community.

New T-cell engagers and ADCs show survival gains in pretreated small cell lung cancer, signaling long-awaited progress and more treatment options for patients.

Although AI can support complex oncology decision-making, physician judgment remains critical to ensuring safe, individualized patient care.



Lauren Yerkes, founder of POST SWIM, discusses the jarring shift to breast cancer survivorship and the daily practice of reclaiming body confidence.

The ATOMIC Trial shows how adding immunotherapy to chemotherapy may reduce recurrence risk and improve outcomes in stage III dMMR colon cancer.

The National Ovarian Cancer Coalition (NOCC) delivers free meals to ovarian cancer patients, easing treatment burdens and supporting caregivers nationwide.

Researchers identified gut microbiome markers that predict melanoma return after surgery, allowing doctors to personalize immunotherapy for patients.

Rezetapopt showed a 44.4% response rate and durable responses over 8 months in ovarian cancer with p53 Y220C mutation, with mostly mild side effects.

Dietitian Stephanie Meyers shared practical strategies at the LiveLung SCLC Patient Summit to help patients manage appetite loss and digestive issues.

Dr. Sunil Dutta discusses treatment approaches and managing side effects in esophageal cancer, including nutrition and patient support strategies.

At NCCN 2026, Dr. Charles Peyton emphasized patient engagement and shared decision-making as expanding treatment options reshape bladder cancer care.

New guidelines back FDA‑approved subcutaneous therapy as effective as IV, letting patients choose faster, easier dosing without losing safety.

Switching from IV to subcutaneous injection eases hard vein access, cuts clinic time, and boosts comfort with faster treatment and fewer side effects.

Dr. Maryam Lustberg discusses the REVITALIZE trial testing CO2 laser therapy to treat vaginal dryness and GSM in breast cancer survivors.

A man with small cell lung cancer describes carboplatin-related hearing loss, fatigue and daily challenges that have reshaped his life, while holding onto perspective and resilience.

At NCCN 2026, Anjali Albanese discussed how young adults with cancer face grief, isolation and loss of control that impact their emotional well-being.

Dr. Michael K. Wong explains why immunotherapy makes skin hypersensitive, and how to spot red-flag reactions during melanoma care.

Dr. Thomas Flaig highlights the importance of multidisciplinary care and clinical trials in guiding personalized bladder cancer treatment decisions.

Dr. Michael Wong shares "sun smart" tips for melanoma survivors, debunking tanning myths and highlighting why clothing is better than sunscreen alone.

The latest episode of the "Breast Cancer Briefing" podcast highlights the evolving integration of GLP-1 agonists into the breast cancer treatment armamentarium.

An expert discusses the need to tailor treatment duration in bladder cancer, balancing improved outcomes with toxicity and exploring new tools.

Dr. Sandy Srinivas explains how age, comorbidities and medications influence personalized prostate cancer treatment decisions.

Meet Dr. Susan MacDonald, a urologist with stage 4 breast cancer who is the host of CURE's new vlog series, "Demystifying the Darkness."

See how subcutaneous immunotherapy cuts clinic time to minutes, streamlining pharmacy prep and avoiding IV access while monitoring toxicity.

Clinical trial data shows subcutaneous nivolumab matches IV effectiveness in kidney cancer, enabling faster, easier immunotherapy dosing.

Persistent heartburn may signal more than GERD. Learn how reflux can lead to Barrett’s esophagus and increase esophageal cancer risk.

Gynecologic oncology is evolving beyond surgery, with greater focus on systemic therapies, team-based care and improved patient outcomes.

Dr. Sheri Prentiss shares how early detection and patient advocacy can prevent chronic lymphedema and improve quality of life for cancer survivors.